Rocket Pharmaceuticals Inc (RCKT)
Healthcare
Biotechnology
3.10 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Rocket Pharmaceuticals Inc (RCKT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 80.3% of the shares are freely tradable; institutional investors hold 89.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
89.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
80.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
24.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
109Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 16.20 | 17,687,772 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 7.83 | 8,544,423 | +24.0 | 12/31/2025 |
| BlackRock Inc | 7.18 | 7,834,795 | -0.9 | 03/31/2026 |
| Citigroup Inc | 4.68 | 5,107,708 | -2.6 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.30 | 4,690,215 | +0.0 | 03/31/2026 |
| State Street Corp | 4.11 | 4,485,989 | +163.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.46 | 3,775,736 | +0.0 | 03/31/2026 |
| Maverick Capital Ltd | 3.27 | 3,567,372 | +42.0 | 03/31/2026 |
| Newtyn Management LLC | 2.90 | 3,165,900 | +19.5 | 03/31/2026 |
| Nuveen, LLC | 2.87 | 3,128,753 | +1,880.1 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.